Ferinject® Assessment in Patients With Iron Deficiency and Chronic Heart Failure (FAIR-HF) (FAIR-HF)
A Randomised Double-blind Controlled Phase III Study to Compare the Efficacy and Safety of Intravenous Iron Carboxymaltose (Ferinject®) With Placebo in Patients With Chronic Heart Failure and Iron Deficiency
Sponsor: ClinStar, LLC
A PHASE3 clinical study on Anaemia and Chronic Heart Failure, this trial is completed. The trial is conducted by ClinStar, LLC and has accumulated 10 data snapshots since 2007. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Nov 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Oct 2021 — Nov 2021 [monthly]
Completed PHASE3
▶ Show 5 earlier versions
-
Jan 2021 — Oct 2021 [monthly]
Completed PHASE3
-
May 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Jan 2019 — May 2020 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2019 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Apr 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- ClinStar, LLC
- Syneos Health
- Vifor Pharma
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Alicante, Spain , Ascoli Piceno, Italy , Athens, Greece , Bad Nauheim, Germany , Barcelona, Spain , Berlin, Germany , Bialystok, Poland , Bilbao, Spain , Brasov, Romania , Bucharest, Romania and 38 more locations